Key result
IV labetalol linked to ~60% higher target BP achievement versus hydralazine in severe pregnancy hypertension.
Why the study?
Response to acute treatment of severe hypertension during pregnancy in Asian women was not known.
Does intravenous labetalol improve prompt achievement of target blood pressure compared to intravenous hydralazine in pregnant women with severe hypertension?
Population
Pregnant Thai women with severe hypertension (SBP >= 160 or DBP >= 110 mm Hg)
Comparison
Intravenous hydralazine (n = 62) vs intravenous labetalol (n = 64)
Design
Retrospective audit review
Authors
Loading...
May support preferring IV labetalol for prompt BP control in severe gestational hypertension; leaves open confirmation by randomized trials.
Cohort (n=126)
Does intravenous labetalol improve prompt achievement of target blood pressure compared to intravenous hydralazine in pregnant women with severe hypertension?
Absolute Event Rate: 67.2% vs 41.9%
p-value: p=< .05
Intravenous labetalol is more effective than hydralazine for prompt blood pressure control and is associated with fewer instances of nonreassuring fetal heart rate in pregnant women with severe hypertension.
Chera-aree et al. (2020) conducted a cohort in Severe hypertension during pregnancy (n=126). Intravenous labetalol vs. Intravenous hydralazine was evaluated on Prompt achievement of SBP 140-150 and DBP 90-100 mm Hg after the first bolus (p=< .05). Intravenous labetalol achieved targeted blood pressure more frequently than intravenous hydralazine (67.2% vs 41.9%, P < .05) in pregnant women with severe hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: